The major contract win for Xcaliber shows the value and potential of its mobile diagnostics solution and Blancco's (LON:BLTGB) (formerly Regenersis) move to bring Xcaliber fully within a broader security and diagnostics offering makes sense. We have raised our earnings forecasts accordingly and continue to believe the shares are attractively valued.
Acquisition and contract progress
Blancco has announced the acquisition of, and a significant new contract win for, Xcaliber. Blancco already held 49% of the venture but has purchased the remainder for a consideration of $5.5m (£3.8m), $4.7m (£3.3m) of which is deferred and contingent upon certain revenue targets being met. We expected Blancco to acquire Xcaliber when it moved from early-stage loss making to profitable on a sustainable basis, but the contract win appears to have triggered Blancco to take control. The contract is multi-year for the roll-out of Xcaliber’s mobile phone diagnostics software across the 5,000+ North American retail base of a major mobile operator and is an extension of an existing 200 store trial. This news follows the announcements of the aftermarket services business disposal completion on 4 April, then the start of the £50m tender offer process on 6 April, which is based on a 215p to 250p range with a close on 4 May.
To read the entire report Please click on the pdf File Below